New combo therapy shows promise for untreated CLL patients
NCT ID NCT01723839
First seen Apr 08, 2026 · Last updated Apr 30, 2026 · Updated 6 times
Summary
This study tested a treatment for people with previously untreated chronic lymphocytic leukemia (CLL). Participants received a combination of chemotherapy drugs (fludarabine and cyclophosphamide) plus the immunotherapy rituximab, along with lenalidomide, followed by lenalidomide alone as maintenance therapy. The goal was to see how many patients achieved a complete response with no detectable cancer cells. The study included 21 participants and aimed to improve outcomes while reducing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Theurer Cancer Center at HackensackUMC
Hackensack, New Jersey, 07601, United States
Conditions
Explore the condition pages connected to this study.